Blackstone Inc vs Charles River Laboratories Intl. Inc — how do they compare? Blackstone Inc trades at $126.26 (market cap $152.15B), while Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B). The key difference: Blackstone Inc is far larger — about 13.7× Charles River Laboratories Intl. Inc's market cap, and Blackstone Inc pays a 3.99% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| BX | CRL | |
|---|---|---|
Market Cap | $152.15B | $11.14B |
Sector | Financials | Health |
52-Week High | $188.68 | $233.60 |
52-Week Low | $102.12 | $145.57 |
Dividend Yield | 3.99% | — |
Enterprise Value | — | $14.00B |
Signals from Pluang's Aura AI — not financial advice
Blackstone (BX) trades at $122.06, down 0.83% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 24.27% net income margin highlight robust profitability, while a $5.34 billion AI infrastructure deal with Williams underscores strategic growth. The stock faces resistance near $123 with support at $121.
Outlook remains positive given consistent earnings outperformance and institutional bullishness, though valuation multiples like a P/E of 31.29 pose risks if growth slows. Key opportunities include AI-driven investments, while macroeconomic volatility and high leverage are concerns.
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →